| The following article features coverage from the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. Click here to read more of Oncology Nurse Advisor‘s conference coverage. |
CHICAGO — Women with chemotherapy-induced ovarian function failure (CIOFF) undergoing anastrozole treatment for early breast cancer may be at increased risk for disease recurrence if they have ovarian function recovery (OFR), despite close monitoring of estradiol levels and adjusting endocrine treatment, researchers concluded in a poster presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Vivianne C. Tjan-Heijnen, MD, PhD, of Maastricht University Medical Centre, Maastricht, The Netherlands, and colleagues selected women who participated in the randomized DATA study, which compared 6 and 3 years of anastrozole therapy in postmenopausal women with hormone-receptor positive early breast cancer previously treated with 2 to 3 years of tamoxifen. The women were aged 45 to 57 years at randomization. The study included women with CIOFF, who may be at increased risk of OFR. All women in the study received adjuvant or neoadjuvant chemotherapy. Investigators classified patients by menopausal status at randomization: 261 patients who were definitely postmenopausal before chemotherapy or by ovariectomy and 395 with CIOFF. Of the CIOFF patients, 39 experienced OFR and 290 did not. The CIOFF patients were monitored by estradiol measurements for OFR during anastrozole therapy.
Continue Reading
The menopausal and CIOFF groups had similar 5-year survival rates. Within the CIOFF group, those with OFR had a non-significant trend toward worse outcomes than those without CIOFF, including a 33% increased risk of disease recurrence and a 2-fold increased risk of both distant recurrence and death after adjusting for tumor size, nodal status, grade, and hormone-receptor status. Patients who had OFR in the first year had a residual 5-year rate of disease-free survival of 73.1% compared with 97.4% of those who did not. The rates were 76.9% vs 92.1% for distant recurrence-free survival, respectively, and 80.8% vs 94.4% for overall survival, respectively, Dr Tjan-Heijnen’s team reported.
Read more of Oncology Nurse Advisor‘s coverage of the 2017 American Society of Clinical Oncology Annual Meeting by visiting the conference page.
Reference
1. Tjan-Heijnen VC, van Hellemnond I, Vriens I, et al. Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. Poster presentation at: 2017 American Society of Clinical Oncology; June 2-6, 2017; Chicago, IL.
